TapewireFind a company

person · Reporting owner

AUSTIN ROXANNE S

Disclosed activity across 7 companies

Tapewire entity
10830
SEC CIK
0001061632

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ABBOTT LABORATORIESABT · Entity 2314DirectorApril 23, 2021April 27, 2021
AbbVie Inc.ABBV · Entity 2800DirectorMay 08, 2026May 12, 2026
CrowdStrike Holdings, Inc.CRWD · Entity 1172DirectorSeptember 14, 2026September 16, 2026
Freshworks Inc.FRSH · Entity 2193DirectorOctober 01, 2026October 02, 2026
TARGET CORPTGT · Entity 2967DirectorJune 02, 2020June 04, 2020
TELEDYNE TECHNOLOGIES INCTDY · Entity 3158DirectorJune 05, 2020June 08, 2020
VERIZON COMMUNICATIONS INCVZ · Entity 116DirectorApril 01, 2026April 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABBOTT LABORATORIES

Report date April 23, 2021 · Filed April 27, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common shares without par valueSEC Table I · non-derivativeDirect41,542 Reported balance After 2021-04-23 transaction · row 1
1 source row

Row 1 · 2021-04-23 · Grant · Acquired 1,499 · Balance 41,542

F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $123.38 · Expires 2031-04-22Direct7,100 Reported balance After 2021-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2021-04-23 · Grant · Acquired 7,100 · Balance 7,100

F2: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Filing footnotes · ownership attribution and instrument terms

F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

AbbVie Inc.

Report date May 08, 2026 · Filed May 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.01 par valueSEC Table I · non-derivativeDirect39,576 Reported balance After 2026-05-08 transaction · row 1
1 source row

Row 1 · 2026-05-08 · Grant · Acquired 1,118 · Balance 39,576

F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Filing footnotes · ownership attribution and instrument terms

F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

CrowdStrike Holdings, Inc.

Report date September 14, 2026 · Filed September 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A common stockSEC Table I · non-derivativeDirect127,040 Reported balance After 2026-09-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-14 · Exercise / conversion · Acquired 50,000 · Balance 127,040

F1: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.

F2: Includes shares to be issued in connection with the vesting of one or more RSUs.

Class A common stockSEC Table I · non-derivativeDirect97,040 Reported balance After 2026-09-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-09-14 · Sale · Disposed 30,000 · Balance 97,040

F3: This transaction was executed in multiple trades at prices ranging from $237.01 to $237.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Includes shares to be issued in connection with the vesting of one or more RSUs.

Class A common stockSEC Table I · non-derivativeDirect77,040 Reported balance After 2026-09-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-09-14 · Sale · Disposed 20,000 · Balance 77,040

F4: This transaction was executed in multiple trades at prices ranging from $238.10 to $238.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Includes shares to be issued in connection with the vesting of one or more RSUs.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.13 · Expires 2028-10-09Direct150,000 Reported balance After 2026-09-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-09-14 · Exercise / conversion · Disposed 50,000 · Balance 150,000

F5: These stock options were granted on October 9, 2018, and vested in 40 equal monthly installments beginning on October 26, 2018.

F1: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.

Filing footnotes · ownership attribution and instrument terms

F1: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.

F2: Includes shares to be issued in connection with the vesting of one or more RSUs.

F3: This transaction was executed in multiple trades at prices ranging from $237.01 to $237.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $238.10 to $238.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: These stock options were granted on October 9, 2018, and vested in 40 equal monthly installments beginning on October 26, 2018.

Freshworks Inc.

Report date October 01, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect213,662 Reported balance After 2026-10-01 transaction · row 1
1 source row

Row 1 · 2026-10-01 · Grant · Acquired 1,513 · Balance 213,662

F1: Represents the grant of fully-vested restricted stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy. Grant reflects director compensation for the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our common stock over the 30 consecutive trading days immediately preceding October 1, 2026, rounded down to the nearest whole share.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of fully-vested restricted stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy. Grant reflects director compensation for the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our common stock over the 30 consecutive trading days immediately preceding October 1, 2026, rounded down to the nearest whole share.

TARGET CORP

Report date June 02, 2020 · Filed June 04, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect34,838 Ending reported balance After 2020-06-04 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2020-06-02 · Exercise / conversion · Acquired 7,415 · Balance 52,253

Row 2 · 2020-06-02 · Sale · Disposed 7,415 · Balance 44,838

Row 3 · 2020-06-04 · Sale · Disposed 10,000 · Balance 34,838

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $60.48 · Expires 2023-01-09Direct0 Reported balance After 2020-06-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-06-02 · Exercise / conversion · Disposed 7,415 · Balance 0

F1: Option granted under the Target Corporation 2011 Long-Term Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Option granted under the Target Corporation 2011 Long-Term Incentive Plan.

TELEDYNE TECHNOLOGIES INC

Report date June 05, 2020 · Filed June 08, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect7,305 Reported balance After 2020-06-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2020-06-05 · Sale · Disposed 1,266 · Balance 7,305

F1: Reporting Person holds 3,305 shares directly and 4,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 3,182 Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting Person holds 3,305 shares directly and 4,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 3,182 Restricted Stock Units.

VERIZON COMMUNICATIONS INC

Report date April 01, 2026 · Filed April 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Phantom StockSEC Table II · derivative / convertible securityIndirectBy Deferred Compensation Plan36,492 Reported balance After 2026-04-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-04-01 · Grant · Acquired 5,062 · Balance 36,492

F1: Each share of phantom stock is the economic equivalent of one share of common stock and is settled in cash. The shares of phantom stock become payable following the reporting person's termination of service as a director.

F2: Includes phantom stock acquired through dividend reinvestment.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of phantom stock is the economic equivalent of one share of common stock and is settled in cash. The shares of phantom stock become payable following the reporting person's termination of service as a director.

F2: Includes phantom stock acquired through dividend reinvestment.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 26, 2017 Filed Apr 28, 2017 19:35 UTC TELEDYNE TECHNOLOGIES INC TDY · Entity 3158 GrantCommon Stock 819 $0.00 $0.00
Disclosure

SEC source: 0001094285-17-000052 · wf-form4_149340811580244.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,458

F1 · security: Represents Restricted Stock Units issued to the Reporting Person under the Administrative Rules of the Amended and Restated Teledyne Technologies Incorporated 2014 Incentive Award Plan Related to Non-Employee Director Restricted Stock Unit Awards and Fees. Each Restricted Stock Unit represents a contingent right to receive one share of Teledyne Common Stock. Units vest one year from the date of grant. Shares of common stock will be delivered to the Reporting Person following the vesting date, unless the Reporting Person has made an election to defer delivery of shares until separation from Board service.

F2 · price: In determining the number of units the price of $134.26 was used.

F3 · balance_after: Reporting Person holds 5,458 shares directly and 2,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 2,966 Restricted Stock Units as of April 26, 2017.

F3 · ownership.direct: Reporting Person holds 5,458 shares directly and 2,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 2,966 Restricted Stock Units as of April 26, 2017.

Read SEC document
January 11, 2017 Filed Jan 13, 2017 18:30 UTC TARGET CORP TGT · Entity 2967 GrantCommon Stock 2,377 $0.00 $0.00
Disclosure

SEC source: 0001225208-17-001069 · doc4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,080

F1 · kind: Award of restricted stock units pursuant to the Amended and Restated Target Corporation 2011 Long-Term Incentive Plan.

F2 · balance_after: Includes dividend equivalents paid on restricted stock units since the date of the reporting person's last filing through the date of the reported transaction that have been reinvested in additional restricted stock units.

Read SEC document
December 02, 2016 Filed Dec 6, 2016 20:08 UTC TARGET CORP TGT · Entity 2967 Exercise / conversionStock Option · Derivative 3,957 $0.00 Strike: $58.13 $0.00
Disclosure

SEC source: 0001225208-16-042777 · doc4.xml · derivative · entry 3

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,957 shares

Expires 2017-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Option granted under the Target Corporation Long-Term Incentive Plan.

Read SEC document
December 02, 2016 Filed Dec 6, 2016 20:08 UTC TARGET CORP TGT · Entity 2967 SaleCommon Stock 3,957 $77.87 $308,146.63
Disclosure

SEC source: 0001225208-16-042777 · doc4.xml · nonDerivative · entry 2

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,522

Read SEC document
December 02, 2016 Filed Dec 6, 2016 20:08 UTC TARGET CORP TGT · Entity 2967 Exercise / conversionCommon Stock 3,957 $58.13 $230,020.41
Disclosure

SEC source: 0001225208-16-042777 · doc4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,479

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes dividend equivalents paid on restricted stock units since the date of the reporting person's last filing through the date of the reported transaction that have been reinvested in additional restricted stock units.

Read SEC document
May 06, 2016 Filed May 10, 2016 21:18 UTC AbbVie Inc. ABBV · Entity 2800 GrantCommon stock, $0.01 par value 2,974 $0.00 $0.00
Disclosure

SEC source: 0001179110-16-024264 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,526

F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 29, 2016 Filed May 3, 2016 21:22 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 3,799 $0.00 $0.00
Disclosure

SEC source: 0001179110-16-023670 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,290

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
May 08, 2015 Filed May 12, 2015 21:50 UTC AbbVie Inc. ABBV · Entity 2800 GrantCommon stock, $0.01 par value 2,187 $0.00 $0.00
Disclosure

SEC source: 0001179110-15-007666 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,552

F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 24, 2015 Filed Apr 28, 2015 21:09 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 2,793 $0.00 $0.00
Disclosure

SEC source: 0001179110-15-006738 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,491

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
May 09, 2014 Filed May 13, 2014 21:20 UTC AbbVie Inc. ABBV · Entity 2800 GrantCommon stock, $0.01 par value 2,764 $0.00 $0.00
Disclosure

SEC source: 0001179110-14-008314 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,365

F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 25, 2014 Filed Apr 29, 2014 21:13 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 3,535 $0.00 $0.00
Disclosure

SEC source: 0001179110-14-007329 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,698

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
May 06, 2013 Filed May 8, 2013 21:09 UTC AbbVie Inc. ABBV · Entity 2800 GrantCommon stock, $0.01 par value 2,535 $0.00 $0.00
Disclosure

SEC source: 0001179110-13-008008 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,601

F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 26, 2013 Filed Apr 30, 2013 21:19 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 3,097 $0.00 $0.00
Disclosure

SEC source: 0001179110-13-007418 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,163

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 27, 2012 Filed May 1, 2012 21:11 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,819 $0.00 $0.00
Disclosure

SEC source: 0001179110-12-007454 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,066

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 29, 2011 Filed May 3, 2011 21:24 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 2,167 $0.00 $0.00
Disclosure

SEC source: 0001179110-11-007240 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,247

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 26, 2011 Filed Apr 29, 2011 01:31 UTC ABBOTT LABORATORIES ABT · Entity 2314 Exercise / conversionOption (right to buy) · Derivative 6,668 $0.00 Strike: $42.73 $0.00
Disclosure

SEC source: 0001104659-11-023805 · a4.xml · derivative · entry 4

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,668 shares

Expires 2011-04-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.

Read SEC document
April 26, 2011 Filed Apr 29, 2011 01:31 UTC ABBOTT LABORATORIES ABT · Entity 2314 SaleCommon shares without par value 2,500 $51.36 $128,402.50
Disclosure

SEC source: 0001104659-11-023805 · a4.xml · nonDerivative · entry 3

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,080

Read SEC document
April 26, 2011 Filed Apr 29, 2011 01:31 UTC ABBOTT LABORATORIES ABT · Entity 2314 SaleCommon shares without par value 4,168 $51.37 $214,093.49
Disclosure

SEC source: 0001104659-11-023805 · a4.xml · nonDerivative · entry 2

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,580

Read SEC document
April 26, 2011 Filed Apr 29, 2011 01:31 UTC ABBOTT LABORATORIES ABT · Entity 2314 Exercise / conversionCommon shares without par value 6,668 $42.73 $284,942.31
Disclosure

SEC source: 0001104659-11-023805 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,748

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 23, 2010 Filed Apr 27, 2010 22:21 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 2,108 $0.00 $0.00
Disclosure

SEC source: 0001179110-10-007454 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,080

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 24, 2009 Filed Apr 28, 2009 22:19 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 2,465 $0.00 $0.00
Disclosure

SEC source: 0001104659-09-026801 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,972

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 25, 2008 Filed Apr 30, 2008 00:18 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,917 $0.00 $0.00
Disclosure

SEC source: 0001104659-08-028086 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,507

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 27, 2007 Filed May 1, 2007 22:08 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,730 $0.00 $0.00
Disclosure

SEC source: 0001104659-07-034470 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,590

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program).

F1 · price: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 28, 2006 Filed May 2, 2006 21:33 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 2,127 $0.00 $0.00
Disclosure

SEC source: 0001104659-06-030321 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,860

F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 22, 2005 Filed Apr 26, 2005 21:24 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon Shares without par value 1,889 $0.00 $0.00
Disclosure

SEC source: 0001104659-05-018221 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,733

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program).

Read SEC document
April 23, 2004 Filed Apr 27, 2004 19:05 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,577 $41.20 $64,972.40
Disclosure

SEC source: 0001104659-04-011388 · a4.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,844

F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.